Kymera Therapeutics(US:KYMR) Globenewswire·2026-02-26 12:00Core Insights - Kymera Therapeutics is advancing a new class of oral small molecule degrader medicines for immunological diseases, with significant progress in its clinical pipeline and financial stability [1][2]. Pipeline Developments - The KT-621 program, a first-in-class oral degrader of STAT6, is currently in Phase 2b trials for atopic dermatitis and asthma, with data expected by mid-2027 and late-2027 respectively [1][3][6]. - The KT-579 program, an oral degrader of IRF5, has initiated Phase 1 trials with data anticipated in the second half of 2026 [1][4][7]. - The company has reported positive Phase 1b results for KT-621 in atopic dermatitis, showing deep STAT6 degradation and significant improvements in clinical endpoints [3][6]. Financial Performance - Collaboration revenues for Q4 2025 were $2.9 million, down from $7.4 million in Q4 2024, while total revenues for the year were $39.2 million compared to $47.1 million in 2024 [11]. - Research and development expenses increased to $83.8 million for Q4 2025 and $316.6 million for the full year, reflecting investment in the STAT6 program and growth in R&D [12]. - The net loss for Q4 2025 was $87.0 million, compared to $70.8 million in Q4 2024, with a total net loss of $311.4 million for the year [14]. Corporate Developments - Dr. Neil Graham has been appointed as Chief Development Officer, bringing over 30 years of biopharma leadership experience [15]. - The company completed a $602 million equity offering in December 2025, ending the year with $1.6 billion in cash, providing a runway into 2029 [15][14]. Upcoming Events - Kymera Therapeutics will hold a video conference call and webcast on February 26, 2026, to discuss its financial results and business updates [16].